Webinar: Updates in Marginal Zone Lymphoma

Listen

Lymphoma Australia invites you to our next free educational webinar tailored to patients, families, and carers of those affected by Marginal Zone Lymphoma.

This session will explore key updates in Marginal Zone Lymphoma, including current treatments and future care approaches.

Event Details

Date: Monday 8th September
Time: 4:00pm to 5:30pm (AEST)

3:30pm to 5:00pm (ACST)

2:00pm to 3:30pm (AWST)

Location: Online via Zoom – Link sent on registration

Cost: Free – Registration required

Guest Presenters

Dr Masa Lasica

Dr Masa Lasica is a haematologist and clinical researcher at St Vincent’s Hospital, Melbourne where she leads the indolent lymphoma and Chronic Lymphocytic Leukaemia (CLL) program. Masa’s clinical research focuses on the use of novel agents to improve outcomes in patients with indolent lymphoma, CLL and multiple myeloma. She is an investigator on a number of national and international clinical studies and is a member of the Australasian Leukaemia and Lymphoma Group and Australasian Lymphoma Alliance.

Dr Jason Hu

Dr Chih-Chiang (Jason) Hu is a haematology advanced trainee at St Vincent’s Hospital, Melbourne where he is involved in the management of patients in both inpatient and outpatient settings to provide holistic care in their treatment journey. He has a broad interest in all areas of haematology and has previously participated and published a quality improvement project aiming at facilitating safe and early hospital discharge after treatments to improve patients’ quality of life. Outside of work, he enjoys cafe hopping and exploring new gourmet food places with his partner.

Spaces are limited so register now to secure your place.

For more info email: nurse@lymphoma.org.au or phone 1800 953 081.

There is limited availability for this event, so secure your spot quickly.

This event has already taken place.

Details

Date: Monday 8th of September 2025

Time: 4:00pm AEST - 5:30pm AEST

For more info email: nurse@lymphoma.org.au or phone 1800 953 081.

Support and information

Patient Online Forum

Find Out More

Order Our Resources

Find Out More

Fundraise for us

Get started

Contact Lymphoma Australia Today!

Patient Support Hotline

General Enquiries

Please note: Lymphoma Australia staff are only able to reply to emails sent in English language.

For people living in Australia, we can offer a phone translation service. Have your nurse or English speaking relative call us to arrange this.

Useful Definitions

Refractory: This means the lymphoma does not get better with treatment. The treatment didn’t work as hoped.
Relapsed: This means the lymphoma came back after being gone for a while after treatment.
2nd line treatment: This is the second treatment you get if the first one didn’t work (refractory) or if the lymphoma comes back (relapse).
3rd line treatment: This is the third treatment you get if the second one didn’t work or the lymphoma comes back again.
Approved: Available in Australia and listed by the Therapeutics Goods Administration (TGA).
Funded: Costs are covered for Australian citizens. This means if you have a Medicare card, you shouldn’t have to pay for the treatment.[WO7]

You need healthy T-cells to make CAR T-cells. For this reason, CAR T-cell therapy cannot be used if you have a T-cell lymphoma – yet.

For more information on CAR T-cells and T-cell lymphoma click here.

Special Note: Although your T-cells are removed from your blood for CAR T-cell therapy, most of our T-cells live outside of our blood – in our lymph nodes, thymus, spleen and other organs.